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Abstract
Attention deficit hyperactivity disorder (ADHD) is a complex psychiatric disorder,
commonly of childhood onset, with profound implications when ineffectively treated.
The core symptoms of inattention, hyperactivity, and impulsivity have implications on
social interactions, educational performance, relationships, and emotional stability
(National Institute of Mental Health, 2017). There is a growing interest for the use of
non-stimulant medications due to the concern over stimulants abuse potential and other
adverse effects. The purpose of this literature review was to increase the knowledge of
Advanced Practice Psychiatric Nurses (APPNs) on the effectiveness of non-stimulants for
the treatment of ADHD in the pediatric population. More specifically, the research on
the non-stimulants atomoxetine, clonidine extended-release (ER) and guanfacine ER will
be analyzed. APPNs have the obligation under their the scope of practice to stay current
on evidence-based practice, promote research, and provide holistic care to the psychiatric
mental health population (American Nurses Association, 2014). By increasing their
knowledge, APPNs will further their ability to provide safe and effective care to the
pediatric population with ADHD. Furthermore, this knowledge can be used to share with
patients and their families during collaborative treatment planning. This paper was
designed to review current research articles from 2007 to present on three ADHD specific
non-stimulant medications. A review of literature was performed using Harley E. French
Library of the Health Sciences utilizing the search engines of CINAHL, PubMed, and
PsycInfo. The literature reviewed found statistically significant results supporting these
non-stimulants as effective medications for children and adolescents with ADHD.
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The Effectiveness of Non-Stimulants for the Treatment of Attention Deficit Hyperactivity
Disorder in the Pediatric Population
Attention deficit hyperactivity disorder (ADHD) is defined as a
neurobehavioral/neurodevelopmental disorder primarily of childhood onset. Inattention,
hyperactivity, and impulsivity are labeled as core symptoms of ADHD, which are also
the main symptoms that are targeted by psychotropic medications (National Institute of
Mental Health, 2017). However, targeting these core symptoms with medications has
been difficult. The common use of stimulants has been under scrutiny by
parents/guardians, media, and health care professionals due to their abuse potential and
other adverse effects like appetite suppression and insomnia (Lakhan & Kirchgessner,
2012). Therefore, there is a demand to find medications that are safe and effective. Thus,
the growing interest for non-stimulants has emerged to treat ADHD.
According to the American Psychiatric Association (2013), 5% of children have
ADHD. There is new criteria for ADHD in the Diagnostic and Statistical Manual of
Mental Disorders Fifth Edition (DSM-V), thus it is estimated that the prevalence may be
closer to 8-12% (Botero-Franco, Palacio-Ortiz, Arroyave-Sierra, & Pineros-Ortiz, 2016).
With the increase in the number of children being diagnosed with ADHD, the number of
children being treated with medications is also increasing. Among adolescents, it is the
most prevailing behavioral disorder and most common reason to seek treatment for
behavioral concerns (Hogue, Bobek, Tau, & Levin, 2014). It is estimated that there has
been a 28% increase in the pharmacological treatment of ADHD in children from 2007 to
2012 (Centers for Disease Control and Prevention, 2017). With the increasing diagnoses
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of ADHD, use of medications, and concern over stimulants, the use of non-stimulants is
also increasing in the pediatric population.
Without proper treatment, ADHD can have a profound effect on a child’s
development. Children with ADHD are affected in their social functioning, education,
interpersonal relations, emotional stability, and family relations (National Institute of
Mental Health, 2017). When there is no treatment or treatment is ineffective at treating
the core symptoms, children have great difficulty thriving in school, socializing with
others, coping with their symptoms, and are at increased risk for substance abuse and
other co-morbid learning and behavioral disorders (Shier, Reichenbacher, Ghuman, &
Ghuman, 2013). There is also growing concern over the use of stimulants and growing
trend in the use of non-stimulants. Therefore, Advanced Practice Psychiatric Nurses
(APPNs) should be knowledgeable in how to safely and effectively treat ADHD in
children. This literature review will provide insight into the effectiveness of nonstimulants in the treatment of ADHD in the pediatric population. The focus of the
literature review will be on the ADHD-specific non-stimulants atomoxetine (Strattera),
clonidine ER (Kapvay), and guanfacine ER (Intuniv).
Purpose
The purpose of this literature review is to provide APPNs with current evidencebased knowledge on the effectiveness of non-stimulants to guide their prescribing
decisions for the treatment of ADHD in the pediatric population. According to the
American Nurses Association (2014), education is the 8th Standard of Practice under their
scope and standards practice for which the APPN utilizes evidence-based research
findings to enhance clinical knowledge. This literature review will also adhere to
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Standard 10, Quality of Practice, by enhancing the APPN’s knowledge to improve their
quality of care, improve their prescriptive decision-making process and therefore enhance
the outcome/effectiveness of the treatment of ADHD in the pediatric population.
Furthermore, Standard 5D Prescriptive Authority and Treatment, states for the APPN to
be knowledgeable in medication’s efficacy, side effects, mechanism of actions, and the
consumers individualized needs when using their prescriptive authority (American
Nurses Association, 2014).
This paper provides education to the APPN on the effectiveness of atomoxetine
(Strattera), clonidine ER (Kapvay), and guanfacine ER (Intuniv) so the APPN can use
this knowledge when choosing treatment plans for children with ADHD while following
the Scope and Standards of Practice by the American Nurses Association. This paper will
define key terms, review and summarize current evidence-based research findings,
describe search methods that were utilized for the research, and discuss the implications
of these findings in regards to the APPN’s role in practice, research, education, and
health policy. With the growing percentage of children being diagnosed and being
treated for ADHD, this knowledge is prudent to improving the quality of care the APPN
delivers to this young population.
Significance
Effectively treating ADHD in the pediatric population does not come easy due to
concerns regarding safety and tolerability of ADHD medications. Using stimulants to
treat ADHD in children has been well researched and proven to be highly effective,
however, these medications have an abuse potential and may cause undesirable side
effects that cause clinicians and parents to prefer not to use these medications and look to

EFFECTIVENESS OF NON-STIMULANTS FOR ADHD

6

other medications that can be effectively used (Martinez-Raga, Ferreros, Knecht, De
Alvaro, & Carabal, 2017). The desire for clinical guidelines for ADHD in pediatrics has
not been overseen. The American Academy of Child and Adolescent Psychiatry (2017)
is creating its first clinical practice guidelines for treating ADHD due to this demand.
Furthermore, the American Academy of Pediatrics has a strong recommendation for
children and adolescents to be treating with Food and Drug Association (FDA) approved
ADHD medications (American Academy of Family Physicians, 2017). With the wellknown and highly publicized knowledge of stimulants holding an abuse potential, the
education of non-stimulants that are FDA approved for ADHD which do not have an
abuse potential should also be publicized regarding their effectiveness. Since nonstimulants are gaining popularity to treat ADHD in the pediatric population, the APPN
needs to be knowledge regarding the their effectiveness to treat ADHD in this population.
It is highly important to know how to effectively treat ADHD with the pediatric
patient because ADHD can have negative outcomes that sustain throughout childhood
and extend into adulthood. Children with ADHD have poorer academic performance
which leads to an increased risk for failing or dropping out. There is also an increase in
relationship problems with other children and family members (Riera, Castells, Tobias,
Cunill, Blanco, & Capella, 2017). Adolescents with ADHD were found to have a poorer
working memory as evident on magnetic resonance imaging in the caudate region,
furthermore, abnormalities were found in the limbic, frontal, and striatal areas (RomanUrrestarazu et al., 2016). Young adults with ADHD are more likely to have legal and
substance abuse problems, and are more prone to injuries (Kovshoff, Williams, Vrijens,
Danckaerts, Thompson, Yardley, & Sonuga-Barke, 2012). Overall, the toll on children
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with ADHD can be exhibited on their mental health, academics, social functioning, and
interpersonal relationships, which leaves them at increased risk for other comorbid
mental health disorders when left untreated or ineffectively treated (National Institute of
Mental Health, 2017).
The APPN’s knowledge of non-stimulant effectiveness will be a valuable tool to
utilize as more and more patients and families are seeking out health care providers that
are specialized in psychiatry. Children with ADHD are considered a vulnerable
population due to their young age and mental health diagnoses thus treatment
management is best to fall under a specialized experienced clinician in this field to yield
the best patient outcomes (Kovshoff, Williams, Vrijens, Danckaerts, Thompson, Yardley,
& Sonuga-Barke, 2012). Due to the DSM-V changing its age criteria for symptoms to
present prior to age 12 verses age 7 in the DSM-IV, it is anticipated that diagnoses will
increase thus will the increase in demand for APPN’s and their prescribing knowledge
and authority to treatment these children (American Psychiatric Association, 2013).
Without a doubt, having the knowledge of non-stimulant effectiveness will positively
increase the safe and effective quality-of-care the APPN can provide the pediatric ADHD
population.
Theoretical Framework
Understanding the pathophysiology of ADHD can help provide a neurobiological
framework to utilize in effectively treating ADHD pharmacologically. In order to know
if a medication is effective at treating a disease, one must understand the pathophysiology
of the disease itself. A prescriber then can choose a medication that has a mechanism of
action that targets the pathophysiology of the disease. When analyzing if a medication is
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effective for a treating a disease, it should target the pathophysiology of the disease itself
and result in positive clinical outcomes of improving symptomology. Under this
framework, children and adolescents with ADHD will have improved outcomes because
the non-stimulant medications are working to target the pathophysiology of the ADHD.
According to Stahl (2013), “in ADHD, imbalances in NE [norepinephrine] and
DA [dopamine] circuits in the prefrontal cortex hypothetically causes inefficient
information processing in prefrontal circuits, and thus the symptoms of ADHD” (p. 475).
More specifically, the neurotransmitters dopamine (DA) and norepinephrine (NE) are
decreased in the prefrontal cortical area of the brain, which results in decreased
stimulation of their receptors. However, symptomology of ADHD not only results from
a decrease in these neurotransmitters but also can results from an excessive amount,
therefore, there needs to be a moderate level of both DA and NE for proper prefrontal
cortex functioning thus improving the symptoms of ADHD. Overall, there should be a
moderate amount of DA to their D1 receptors and moderate amount of NE to their α2A
receptors (Banaschewski et al., 2005). In fact, “properly tuned D1 receptor stimulation
will reduce noise while α2A receptor stimulation will increase the signal, resulting in
appropriate prefrontal cortex functioning, guided attention, focus on a specific task, and
control of emotions and impulses” (Stahl, 2013, p. 483).
Atomoxetine is known as a norepinephrine transporter (NET) inhibitor, which
selectively inhibits NE reuptake in the prefrontal cortex. This reuptake inhibition causes
an increase in NE and therefore an increase in DA since NETs can also transport DA. By
targeting NETs, which are plentiful in the prefrontal cortex, atomoxetine can target
symptoms of ADHD. Furthermore, this increase in NE and DA occurs through tonic
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signaling by downregulation of any phasic actions of NE and DA resulting in the desired
moderate tonic controlled release. There is also no abuse potential with atomoxetine
because there are few NE neurons with NETs in the nucleus accumbens, which is known
as the reward/abuse center of the brain, additionally, there is no phasic firing which
occurs with immediate release stimulants (Stahl, 2013).
Another way to target NE in the prefrontal cortex is by using an α2 receptor
agonist such as clonidine. α2A receptors are highly concentrated in the prefrontal cortex
thus agonizing α2A receptors causes an increase NE here, which then targets ADHD
symptoms. Even though clonidine is an α2 receptor agonist, it is not selective to the α2A
receptor. Clonidine also has actions on imidoazoline, α2B, and α2C receptors, which can
be blamed for clonidine’s side effects, but also why clonidine can also have other
therapeutic effects not specific to the ADHD symptomology (Stahl, 2013). The
extended-release (ER) form of clonidine known as Kapvay, allows of tonic (controlled
release) of NE throughout the day.
Similar to clonidine, guanfacine is also an α2 receptor agonist. However,
guanfacine is highly selective to the α2A receptor, approximately 15-60 times more
selective than clonidine (Stahl, 2013). Therefore, guanfacine is more potent to the α2A
receptors in the prefrontal cortex in targeting the core symptoms of ADHD that are
manifested in this area of the brain.
Understanding the role of the DA and NE and their receptors in ADHD is
essential to guide the APPN’s prescribing decision-making. Therefore, it is imperative
that the APPN is also knowledgeable on the mechanism of action of non-stimulants at
targeting the key neurotransmitter pathways and their receptors that are underlying the

EFFECTIVENESS OF NON-STIMULANTS FOR ADHD

10

pathogenesis of ADHD. With this knowledge, the APPN can prescribe non-stimulants
knowing that their mechanism of action can effectively target the pathophysiology of
ADHD leading to improved symptoms. In this review of literature, evidence-based
research articles on atomoxetine (Strattera), clonidine ER (Kapvay), and guanfacine ER
(Intuniv) will be discuss as well as their clinical outcomes.
Definitions
ADHD: An abbreviation for Attention Deficit Hyperactivity Disorder, which is a
neurobehavioral disorder commonly of childhood onset with three primary symptoms of
inattention, hyperactivity, and impulsivity (National Institute of Mental Health, 2017).
Pediatric: Generalized term for the population of children and adolescents (National
Institute of Mental Health, 2017).
Children: Human being prior to puberty; ages 6-12 (National Institute of Mental Health,
2017).
Adolescents: Human being during the pubertal time; ages 13-18 (National Institute of
Mental Health, 2017).
ER: An abbreviation for “extended-release” formulation of a mediation, which causes a
slow, controlled-release of a medication over a longer period of time. Similar names for
extended-release are SR “sustained-release” and CR “controlled-release”. In some
publications one may see extended-release abbreviated as XR (Stahl, 2013).
Effectiveness/efficacy: Producing the desired effect of a medication’s intention (Stahl,
2013).
Statistically significant: In research, the relationship of a study’s findings was not due to
chance; p-value is less than 5% (Stahl, 2013).
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Process
A literary search was performed using the University of North Dakota’s Harley E.
French Library of the Health Sciences to locate research articles on the effectiveness of
non-stimulants for the treatment of ADHD in the pediatric population. The search
engines of PubMed, CINAHL, and PyscInfo were utilized due to their specialization in
nursing, medicine, health, life, and psychology.
The literature search began with PubMed with the use of MeSH (medical subject
heading) terms and using limitation of the last 10 years, peer-reviewed, and English
language. The use of the MeSH terms “ADHD” AND “pediatric” AND “atomoxetine”
resulted in 129 articles, “ADHD” AND “pediatric” AND “clonidine ER” resulted in 24
articles, and “ADHD” AND “pediatric” AND “guanfacine ER” resulted in 39 articles. A
review of the titles, abstracts, and keywords within the articles were scanned and 21
articles were found applicable to the literature review topic. After reading the articles,
eight were chosen for inclusion into the literature review portion of the paper.
The CINAHL database was then searched using Boolean Connectors and
CINAHL Headings and the limitations of 2007-2017, peer-reviewed, English language,
and human subjects. “ADHD” AND “pediatric” AND “atomoxetine” was searched and
resulted in 17 articles, “ADHD” AND “pediatric” AND “clonidine ER” and resulted in
two articles, and “ADHD” AND “pediatric” AND “guanfacine ER” and resulted in two
articles. After reviewing the articles, 13 were eliminated due to the content and age
limitations not being congruent with the literature review topic and repetitive articles that
were found during the PudMed search, leaving four articles that were chosen to be
included in the paper.
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PsycInfo was another database that was used to gather pertinent articles to the
literature review topic with the use of Boolean Connectors with the same limitations as
the CINAHL search. “ADHD” AND “pediatric” AND “atomoxetine” was searched and
resulted in 33 articles, “ADHD” AND “pediatric” AND “clonidine ER” and resulted in
seven articles, and “ADHD” AND “pediatric” AND “guanfacine ER” and resulted in
seven articles. After reviewing the articles, 35 were found to not be applicable to the
literature search topic or had repetitive data. Six articles were found to be repeat articles
of the ones found in the PubMed and CINAHL searches and they were eliminated,
leaving three articles for inclusion in the paper.
The information that is in this literature review has been obtained through the
literature search, which is described above and has been formatted into an informative
PowerPoint presentation (see Appendix). The PowerPoint presentation will be emailed to
the University of North Dakota Psychiatric Mental Health Nurse Practitioner student
class of 2018. Presenting this PowerPoint to this cohort during their senior year allows
for the opportunity for them to share these findings during their clinical practicums.
Increasing the knowledge of the effectiveness of non-stimulants for ADHD in the
pediatric population to APPN’s allows for evidence-based treatment planning for their
patients.
Review of Literature
According to the American Academy of Pediatrics (2011), children with ADHD
over the age of 6 have a strong recommendation, quality of evidence level A
(strongest/highest recommendation), to be prescribed a food and drug administration
(FDA)-approved medication for ADHD and/or behavioral therapy. Furthermore, these
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guidelines state, “the evidence is particularly strong for stimulant medications and
sufficient but less strong for atomoxetine, extended-release guanfacine, and extendedrelease clonidine (in that order) (quality of evidence level A)”, (American Academy of
Pediatrics, 2011, p. 2). With the support of the FDA by their approval for atomoxetine,
clonidine ER, and guanfacine ER as ADHD specific non-stimulants, the APPN should be
knowledgeable regarding each of these medication’s unique outcomes in targeting the
symptomology of ADHD in the pediatric population. This literature review will analyze,
critique, and summarize research articles that have addressed the effectiveness of these
non-stimulants specifically in the pediatric population.
Atomoxetine (Strattera)
Two similar randomized control trials (RCTs) were found during this literature
search that analyzed atomoxetine and a placebo. The first was a randomized, double
blind placebo-controlled trial, which was conducted with atomoxetine in children and
adolescents from age ranges 6-16 years old with a DSM-IV diagnosis of ADHD to
determine efficacy. This trial took place in Russia, was 6-weeks long, and contained 105
patients with 72 receiving atomoxetine and 33 receiving the placebo. The results of this
trial were statistically significant according to the Attention-Deficit/Hyperactivity
Disorder Rating Scale-IV-Parent Version (ADHD-RS-IV-Parent) scores; which includes
scales for inattention, impulsivity, and hyperactivity. The comparative baseline to
treatment response after 6 weeks for atomoxetine was 72.2% and the placebo 48.5%
(Martenyi et al., 2010). It was also noted that patients who received atomoxetine had a
more rapid clinical outcome response.
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Secondly, according to Weiss, Tannock, Kratochvil, Dunn, Velez-Borras,
Thomason, & Allen (2005), atomoxetine was found to be effective in treating ADHD
symptoms in a RCT using atomoxatine and a placebo in 153 children with ADHD ages 812 years old. A similar scale was used as the previously mentioned study, however
instead of parents evaluating the child, the teacher did using the ADHD-RS-IV-Teacher
scale. This scale was administered at baseline and at 7 weeks resulting with the
atomoxetine group having 69% decrease of at least 20% in symptoms of inattention,
hyperactivity, and impulsivity compared to the placebo of 43.1% (Weiss, et al., 2005).
As with the previously mentioned study, it was also found to have quick onset of
symptom improvement starting at only one week.
Nagy, Häge, Coghill, Caballero, Adeyi, Anderson, and Cardo (2016) found
another way to determine effectiveness of atomoxetine in children with ADHD by using
the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). In doing so, a
randomized control, double-blinded trial of atomoxetine and lisdexamfetamine
dimesylate was performed with 200 children with ADHD from ages 6 to 17 years old.
For the focus of this literature review, only atomoxetine’s effectiveness will be analyzed.
The WFIRS-P “comprises 50 items, grouped into six domains (Family, Learning and
School, Life Skills, Child’s Self-Concept, Social Activities, and Risky Activities)” and
was administered to parents or guardians at baseline and at 9 weeks (Nagy, et al., p.143,
2016). Atomoxetine was found to have statistically significant results showing a
decrease in all six domains of the WFIRS-P with the largest decrease in the family,
learning, and school domains.
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An important limitation of these studies to note is their short duration of less than
12 weeks. Atomoxetine can take up to 12 weeks or more to reach maximum potential,
therefore, any study that is less than 12 weeks may be not be resulting in the full
treatment potential that atomoxetine has (Nagy, 2016). Subjective scales can also limit
some of the studies validity due to its openness for human interpretation and subjectivity;
however, due to the nature of the ADHD’s symptomology it would be difficult to
eliminate this bias. Strengths of the studies include the research designs of randomized
blinded studies and specific patient populations and diagnoses. There remain gaps in the
research for making more specific outcome measurement scales that are more inclusive
of the patient’s report, larger patient populations, and longer duration of studies.
A more recent study by Nakanishi, Ota, Iida, Yamamuro, Kishimoto, Okazaki, &
Kishimoto (2017) utilized a more objective tool to measure the effectiveness of
atomoxetine and the stimulant medication of methylphenidate. Oxyhemoglobin level
measured by near-infrared spectroscopy (NIRS) was obtained during a stroop color-word
test on 30 children with a diagnosis of ADHD ages 6-14. A probe was placed over the
patient’s frontal orbital regions to obtain oxyhemoglobin levels, which indicates
prefrontal cortex activity. Levels were obtained every 0.1 seconds throughout the stroop
color-word test, with readings averaged over 10 seconds. NIR measurements were
obtained pre-treatment and 12 weeks after atomoxetine was started, which is a strength of
the study by having a long enough time frame to match the therapeutic effects of
atomoxetine. However, a major limitation was the small number of participants and their
treatment group was not randomly assigned, a pediatric psychiatrist assigned them (with
methodology unknown).
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The results of the actual stroop word-color test was also analyzed which is an
indicator of selective attention in execute functioning, known to be decreased in children
with ADHD. There were statistically significant improvements in the stroop color-word
test from pre-medication to 12 weeks after starting atomoxetine. It was also noted that
there was positive correlation between age and scores. Furthermore, the NIRS
oxyhemoglobin levels had substantial increases from pre-medication to 12 weeks after
the start of atomoxetine. More specifically, the left lateral frontal lobe had the greatest
increase in oxyhemoglobin levels. Interesting to note, although beyond the scope of this
literature review, methylphenidate did not show any improvement in oxyhemoglobin
levels (Nakanishi et al., 2017).
The meta-analysis by Schwartz & Correll (2014) helped pull together results of 25
double-blinded RCTs that used atomoxetine and a placebo with children with ADHD.
Again, the results favored atomoxetine over the placebo, 44.6% of patients had
improvement of symptoms of 40% or higher. However, there were 39.9% of patients
who did not respond with over 25% improvement of their symptoms. The results were
similar throughout the childhood years and results did not differ from children to
adolescents. Therefore, the authors agreed that there are patient specific factors that need
further research in why some pediatric patients respond well and other do not. When
reviewing the studies, the authors felt that limitations for this RCT is generalizing the
results to the whole pediatric ADHD population because only certain patients may be
exposed to the opportunity to participate in these studies.
Clinical trials, as mentioned above, have shown atomoxetine to be effective at
targeting the core symptoms of ADHD in children. There are factors that affect
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atomoxetine’s effectiveness. In order for atomoxetine to be effective it must be dosed
appropriately and maintained in a therapeutic window. Children who lack the CYP2D6
enzymatic pathway or are rapid metabolizers will have a difficult time metabolizing the
medication and maintaining that therapeutic window; therefore, the FDA makes
prescribers aware of these dosing instructions for CYP2D6 sensitive children on its
packaging label (Dean, 2012).
A review of literature by Kohn, Tsang, & Clarke (2012) concluded atomoxetine to
be efficacious in children who also have anxiety or tic related disorders. The efficacy
also was not altered by other comorbid conditions and allowed for atomoxetine to
maintain a therapeutic effect. In addition, health related quality of life results were
positively correlated with short and longer-term studies of atomoxetine in children with
ADHD.
Clonidine ER (Kapvay)
Clonidine ER, the generic form is labeled Kapvay, is the only formulation of
clonidine that is approved by the FDA for the treatment of ADHD in the pediatric
population (immediate release is not). A systemic review by Chan, Fogler, &
Hammerness (2016) found clonidine ER effective as monotherapy and as an adjunct with
stimulants therapy for children with ADHD ages 6-17. Studies regarding the effects of
clonidine ER monotherpay are limited due to a greater interest in clonidine ER/stimulant
combination therapy.
As with atomoxetine, there was been a couple statistically significant RCTs
performed using a placebo-control to determine the effectiveness of clonidine ER. A
shorter RCT of only 8 weeks compared clonidine ER and a placebo looking at various
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aspects of ADHD in children ages 6-17 years old. Statistically significant improvements
were found between pre-medication and at the 8-week mark on scales of ADHD-RS-IV,
Conner’s Parent Rating Scale, Parent Global Assessment, and Clinical Global Impression
of Improvement and Severity Scales. As with atomoxetine, clonidine ER demonstrated a
quick response to treatment starting as soon as two weeks. A major limitation of this
study is the short duration of the study and that it only had a sample size of 236 patients.
The study also required same dose titrations during this 8-week period; which limits the
individual therapeutic needs of the patient (Jain, Segal, Kollins, & Khayrallah, 2011).
Palumbo, Sallee, Pelham, Bukstein, Daviss, & McDermott, (2008) published a
slightly longer RCT of 16 weeks, which strengthens the study, however, it was performed
on only 122 children ages 7-12, which then limits the study due to its small size.
Clonidine ER, methylphenidate, or a combination of the two medications were analyzed
at pre-medication and every 4 weeks for a total of 16 weeks using 3 different scales:
Conners Teachers Abbreviated Symptom Questionnaire, Conner’s Abbreviated Symptom
Questionnaire for Parents and Children's Global Assessment Scale.
Each scale produced differing results regarding the efficacy of clonidine ER. The
Conner’s Teachers Abbreviated Symptom Questionnaire did not result in improvement of
ADHD symptoms in the clonidine ER monotherapy group, but did show improvement in
the combination of clonidine ER/methylphenidate group. The Conner’s Abbreviated
Symptom Questionnaire for Parents and Children's Global Assessment Scale however did
show improvement in ADHD symptoms whether it was in the clonidine ER monotherapy
group or the combination group. Even though the results were not robust for clonidine
ER, the authors believe clonidine ER is efficacious for certain ADHD patient subtypes
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such as those with co-morbid behavioral and/or impulsive disorders (Palumbo et al.,
2008).
To look even further into the efficacy of adding clonidine ER to stimulants,
Kollins, Jain, Brams, Segal, Findling, Wigal, & Khayrallah, (2011), published a
randomized double-blinded trial that used either clonidine ER or a placebo to a current
stimulant treatment plan that was not effective. Clonidine ER was not evaluated as
monotherapy. There were a total of 198 children and adolescents enrolled over this 8week study. A strength of this study was reported to be a diverse patient population of
males, females, children and adolescents. Limitations include excluding comorbid
disorders; which eliminates many of the ADHD populations that have co-existing
learning or behavioral disorders, and the variability in stimulant medications.
The ADHD-RS-IV scale was administered at baseline, week 2, week 5, then
weekly through out the 8 week study. At week 2 there was no differences from baseline
scores between the clonidine ER combination group and the placebo combination group.
Starting at week 5 the clonidine ER combination group started to show statistically
significant results, which continued throughout the remainder of the study. Hyperactivity
and inattention subscale scores with the ADHD-RS-IV were analyzed showing statistical
significant is these subcategories. To strengthen this study, the Conner Parent Rating
Scale, Clinical Global Impression of Severity and Improvement, and Parent Global
Assessment were also analyzed at the same week intervals as the primary ADHD-RS-IV
scale and were all found to have statistically significant improvements in their scores for
the clonidine ER combination group (Kollins et al., 2011).
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Guanfacine ER (Intuniv)
In 2009, the FDA approved the extended release form of guanfacine ER called
Intuniv. A literature review by Strange (2008) found guanfacine ER to have profound
effects on executive functioning in children by improved attention spans, impulse control,
planning, working memory, and distractibility. This is in support of the theory of
guanfacine’s mechanism of action working in the prefrontal cortex. Improvements in
behaviors and motor control can be attributed to guanfacine’s effects on the
noradrenergic projections to the basal ganglia and cerebellum.
Two RCTs had profound impacts on the FDA decision to approve guanfacine ER
in the pediatric population for ADHD.

Sallee et al. (2009) published an RCT that was a

double-blinded comparison of guanfacine ER and a placebo; the guanfacine ER group
was divided into 3 separate dosage groups. Three hundred twenty-nine children and
adolescents aged 6 to 17 years old were evaluated with the ADHD-RS-IV scale prior to
the start of the trial and 9 weeks after the start of the trial. Averaged improvements in
ADHD-RS-IV was reported for all three guanfacine ER dosage groups showing a
reduction in score of 19.6, compared to the placebo which had a reduction of 12.2. More
specifically, the subscales of the ADHD-RS-IV scale in categories of inattention,
hyperactivity, and impulsivity, all had significantly improved scores in the guanfacine ER
groups over the placebo group. Strict inclusion and exclusion criteria were strengths of
the study with limitations included a short 9-week trial duration and a small number of
adolescents compared to children (Sallee et al., 2009).
A very similar double-blind RCT of 345 children and adolescents (ages 6-17
years old) also compared guanfacine ER with 3 different dosage groups and a placebo.
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Efficacy was also determined using the ADHD-RS-IV scale prior to the start of the trial
and at 8 weeks. Again, subscales for inattention, hyperactivity, and impulsivity were
analyzed with all categories resulting in statistically significant improvement in the
guanfacine ER groups. The average changes in scores for the guanfacine ER groups
were 17.16 and the placebo group was 8.48 (Biederman, Melmed, Patel, McBurnett,
Konow, Lyne, & Scherer, 2008). This study also used secondary efficacy scales of
Clinical Global Impression of Improvement, Parent's Global Assessment, Conner’s
Parent and Teacher Rating Scale–Revised, and Conner’s' Teacher Rating Scale–Revised
and found significant improvements in the guanfacine ER groups. Again, this study was
limited by its short duration.
These two RCTs provided valid statistically significant results as indicated by the
ADHD-RS-IV scale and subscales. Monotherapy for guanfacine ER for ADHD in the
pediatric population was found to be efficacious. A literature review by Faraone,
McBurnett, Sallee, Steeber, & López (2013) found varying results in the efficacy onset of
action for guanfacine ER, ranging from 1-4 weeks. In addition, guanfacine ER was
found to be favorable for pediatric patients with ADHD that had dominant oppositional
symptoms.
In 2011, the FDA approved guanfacine ER as an adjunct to stimulant treatment
for pediatric patients with ADHD aged 6-17. This combination was found to be
beneficial in children who were not experiencing the full treatment potential of stimulant
medications. In addition, ADHD-RS-IV scores saw improvements with guanfacine
ER/stimulant combination therapy in children with opposition symptoms and those
without (Childress & Berry, 2012).
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The pivotal RCT approving guanfacine ER/stimulant combination treatment
efficacious, was published by Wilens, Bukstein, Brams, Cutler, Childress, Rugino, &
Youcha, (2012). This was a larger scale study of 461 participants of children and
adolescents with ADHD aged 6-17. It was double-blinded with participants randomly
adding either guanfacine ER or a placebo to their current stimulant medication. A
strength of this study was that it also used the ADHD-RS-IV scale, which has been
commonly used in other ADHD medication trials. A limitation of this study was the
possible difficulty of assessing efficacy because a requirement was for a partial response
in stimulant therapy already before entering the trial. A shorter duration of 9 weeks was
another reported limitation.
Scores from the ADHD-RS-IV scale and subscales, in addition, Clinical Global
Impressions of Severity of Illness and Improvement scales were averaged for the
guanfacine ER/stimulant group and placebo/stimulant group. There were significant
improvements in scores for all assessment scales for the guanfacine ER/stimulant group
verses the placebo/stimulant group. The study had also compared morning and evening
doses of each treatment group. When analyzing the guanfacine ER/stimulant treatment
group, there were no differences in assessment scales for efficacy whether the medication
was administered in the am or pm. Overall, guanfacine ER was shown effective as an
adjunct to stimulant therapy for children and adolescents with ADHD (Wilens et al.,
2012).
Results
The comprehensive literature search through CINAHL, PubMed, and PsycInfo
resulted in 15 articles that were reviewed, evaluated, and deemed relevant to the literature
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review topic of the effectiveness of non-stimulants in the treatment of ADHD in the
pediatric population. A summary of the type of studies within these 15 articles include
nine RCTs, three literature reviews, one non-randomized study, one meta-analysis, and
one systemic review. RCT studies were found to be very beneficial because there was
elaboration on the specific types of outcome measurement tools that were utilized. The
most common scale that was used was the ADHD-RS-IV-Parent and the Clinical Global
Impression and Severity Scale. Other scales that were also utilized were the ADHD-RSIV-Teacher, WRIRS-P, Connors Parents and Teacher Rating Scale, and the Parent Global
Scale. Most of these scales had either a parent/guardian or teacher completing the scale.
The non-randomized study did not use a scale; the Stroop Word-Color Test and NIRS
score was performed instead.
Six out of 15 chosen articles studied the effectiveness of atomoxetine with all in
agreement of atomoxetine as being an effective medication for the treatment of ADHD in
the pediatric population. The articles had statistically significant results supporting
atomoxetine’s effectiveness and two found atomoxetine to have more rapid onset than the
placebo. One study found the NIRS (near-infrared spectroscopy) exam to have increased
prefrontal cortex activity especially in the left lateral frontal lobe when on atomoxetine.
Four out of the total 15 articles found clonidine ER to have statistically significant
results supporting its efficacy for the treatment of ADHD in the pediatric population.
Two out of the three RCT’s compared the effectiveness of clonidine ER as an adjunct
medication to stimulant treatment. The systemic review highly supported the use of
clonidine ER as an adjunct medication to stimulant therapy and found clonidine ER to be
more helpful with behavioral symptoms.
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Five out of the total 15 articles also found guanfacine ER to have statistically
significant results. Guanfacine ER was found to be an effective adjunct to stimulant
treatment in 3 out of the 5 articles. One article found guanfacine ER to be specifically
efficacious in children with oppositional symptoms.
All 15 articles found atomoxetine, clonidine ER, and guanfacine ER as effective
non-stimulants to treat ADHD in the pediatric population. The scales that were utilized
measured inattention, hyperactivity, and impulsivity; also, depending on the scale,
measured domains such as family, social, and psychological symptoms. These outcome
measurement scales varied between research studies; however, due to their similar
outcomes they were measuring, their outcomes were found to be clinically significant.
The PowerPoint presentation (see Appendix) will include these results along with all the
other sections of this paper and will be delivered to the University of North Dakota
Psychiatric Mental Health Nurse Practitioner student class of 2018. The purpose of this
literature review is to increase knowledge therefore feedback regarding this literature
review is not required but is welcomed.
Discussion of Implications in Nursing
Practice
Implications of this literature review can impact the APPN’s practice by
providing the APPN with knowledge to deliver holistic patient-centered care. The
decision to choose non-stimulants over the best practice guideline of stimulants, can
demonstrate how the APPN is providing holistic care by addressing all aspects of the
patients needs and concerns. When parents/guardians refuse for their child to be
medicated for ADHD, it is important to explore their concerns and assess their
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knowledge regarding available FDA approved ADHD medications for children and
adolescents. Parents/guardians may not be aware that non-stimulant medications can
effectively treat ADHD in the pediatric population; therefore, the APPN should offer a
complete review of medication alternatives. The content of this literature review was not
conclusive to determine if a non-stimulant should be prescribed, rather it reviews an
option for treatment. Additional factors when prescribing that go beyond the scope of
this literature review should be assessments for side effects, drug interactions, co-existing
medical conditions, allergies, etc.
Due to the potential adverse outcomes that can occur if children and adolescents
are not effectively treated for ADHD, the APPN should strive for providing the most upto-date, comprehensive, knowledgeable care. It is important to not become stagnant in
one’s practice. Continuing to educate oneself is essential as new evidence-based research
becomes published and understanding of the brain and how it relates to mental illness is
ever increasing.
Research
The literature search and review of articles did reveal quantity and quality of
research on the topic of non-stimulant effectiveness for ADHD treatment in the pediatric
population. There was an abundance of research regarding stimulant treatment for
ADHD and ADHD treatment for adults not used in this review. The literature search
resulted in 15 articles that were specific to the ADHD pediatric population, which was
very small compared to the search for the adult ADHD population. Furthermore, there
was difficulty in finding research that was purely measuring the effectiveness of a nonstimulant. Many articles evaluated stimulant therapy and/or stimulant with adjunct non-
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stimulant therapy. This was found to be particularly true when researching clonidine ER
and guanfacine ER. These two non-stimulants had more research regarding their
effectiveness when used as an adjunct with stimulants than atomoxetine did. Additional
research would be beneficial to support clonidine ER and guanfacine ER as monotherapy
medication treatment for ADHD in children and adolescents.
Even though the research articles provided statistically significant results, there
was contrast throughout studies regarding outcome measurement scales. To ensure
consistency and validity in research, standardized outcome measurement scales would be
preferred. Interesting to note, most scales used were given to parent/guardians or
teachers. More research is needed to determine what outcome measurement scale is best
to determine effectiveness of a medication for pediatric patients with ADHD. A scale
that also incorporates the patient’s input may be useful.
In addition, limitations within each study could be improved upon. Sample size
and duration of study were common limitations that are mendable. With the
understanding of non-stimulant’s mechanism of action in regards to duration time of peak
effectiveness, proper study durations could be utilized. It is common for studies to have
smaller sample sizes for pediatric research patients due to ethical concerns. However,
larger samples sizes will increase validity and statistically significant results. Ongoing
research is necessary to keep information current on the effectiveness of these and other
medications for the treatment of ADHD.
Education
The purpose of this literature review is to give education to APPNs by providing
information on the effectiveness of non-stimulants for children and adolescents with
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ADHD. By presentation of a PowerPoint prepared educational tool, APPNs may gain
knowledge of the research articles that have been published which have contributed to the
FDA’s decision to approve atomoxetine, clonidine ER, and guanfacine ER as nonstimulant treatment for ADHD in the pediatric population. The knowledge gained from
this educational tool can be used for increasing the treatment options of children and
adolescents with ADHD.
Understanding the mechanism of action of the non-stimulants, as described
previously, is important when determining what medication is best for a patient. It is
important for the APPN to be educated on medications, including their evidence-based
research. That knowledge can be used not only for treatment decisions but also for
providing pyschoeducation to their patients (American Nurses Association, 2014). With
knowledge of the evidence-based research, the APPN can educate the patient and their
parents/guardians regarding its effectiveness and how the medication will target the core
symptoms of ADHD.
Health Policy
Implications of the findings of this literature review can be used as part of an
educational tool to make changes to health policies at varying levels. Policies at
hospitals, outpatient settings, and state levels can be impacted by the results of this
literature review by APPN’s advocating for updated policies for treatment options.
Furthermore, the APPN can support continuing research by seeking out research studies
and supporting their clients they choose to enroll.
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Conclusion
ADHD is a complex disorder with the potential to leave profound effects on one’s
childhood and development when not treated effectively. This literature review focused
on the effectiveness of non-stimulants for the treatment of ADHD in the pediatric
population and found statistically significant results supporting their use. The literary
search of atomoxetine, clonidine ER, and guanfacine ER found statistically significant
results despite the use of differing yet similar outcome measurement scales. Even though
the research proved significant results, which helped support the FDA in approving these
non-stimulants for the treatment of ADHD in children and adolescents, continuing
research is need to maintain these medications as treatment options for this population.
The reviewed research studies were found to have limitations due to their short study
duration. There is a need for more research studies with longer duration, greater sample
size, and with a focused monotherapy experimental group to strength the validity of their
findings.
With the results of this literature review and the developed educational
PowerPoint tool, the APPN can make more knowledgeable decisions during treatment
planning for their pediatric patient with ADHD. In addition to the APPN having
increased knowledge to make their educated decision, the APPN will also have another
educational tool to utilize during medication education with parent/guardians and the
patient. The APPN will be equipped to engage in comprehensive treatment planning with
families. Providing optimal quality of care to children and adolescents with ADHD gives
these clients the opportunity for growth and development similar to their peers not
affected by this condition. This literature review demonstrates that APPNs need to stay
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informed of current research findings on ADHD treatment and support ongoing research
of evidence-based treatment options in this area. It would be anticipated that APPNs who
empower themselves with this type of knowledge would have professional growth and
satisfaction in delivering care to pediatric patients with ADHD.
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Effectiveness of Non-Stimulants
for the Treatment of
Attention De8icit Hyperactivity Disorder
in the Pediatric Population
This is a presenta,on of a literature review by:
Rebecca Gonzalez, Psychiatric Mental Health Nurse Prac,,oner student
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Introduction to ADHD
• Neurobehavioral/
neurodevelopmental
disorder
• Primarily of childhood
onset
• Core symptoms:
ina:en;on,
hyperac;vity,
impulsivity
• Core symptoms are
targeted by
pharmacology
(Na;onal Ins;tute of Mental Health, 2017)

• According to the
American Psychiatric
Associa;on (2013), 5%
of children have ADHD
• There is new criteria
for ADHD in the DSMV, thus it is es;mated
that the prevalence
may be closer to 8-12%
(Botero-Franco, Palacio-Or;z, Arroyave-Sierra,
& Pineros-Or;z, 2016)

31

EFFECTIVENESS OF NON-STIMULANTS FOR ADHD

Introduction to the use of nonstimulants for ADHD
• There is a 28% increase in the pharmacological
treatment of ADHD in children from 2007 to 2012
(Centers for Disease Control and Preven@on, 2017)

• Implica@on of ineﬀec@ve treatment include:
diﬃculty with school performance, socializing with
others, coping skills, & there is an increased risk for
substance abuse and other co-morbid learning and
behavioral disorders (Shier, Reichenbacher, Ghuman, & Ghuman, 2013)
• Use of non-s@mulants is increasing due to…the
increasing diagnoses of ADHD, increased
pharmacological treatment, and concern over
s@mulants
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This literature review analyzed the eﬀec4veness of the
3 FDA approved non-s4mulants

atomoxe4ne (StraAera)
clonidine ER (Kapvay)
guanfacine ER (Intuniv)
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Purpose
Provide APPNs with current evidence-based knowledge on the
eﬀec9veness of non-s9mulants to guide their prescribing decisions for
the treatment of ADHD in the pediatric popula9on
This knowledge is per0nent for APPNs to follow their Scope and
Standards of Prac0ce by the American Nurses Associa0on
• 8th Standard of Prac0ce-EDUCATION: APPN u0lizes evidence-based
research ﬁndings to enhance clinical knowledge
• 10th Standard of Prac0ce-QUALITY OF PRACTICE: Enhancing the
APPN’s knowledge to improve their quality of care, improving their
prescrip0ve decision-making process and therefore enhancing the
outcome/eﬀec0veness of the treatment of ADHD in the pediatric
popula0on
• 5D Standard of Prac0ce-PRESCRIPTIVE AUTHORITY and TREATMENT:
To be knowledgeable in medica0on’s eﬃcacy, side eﬀects, mechanism
of ac0ons, and the consumers individualized needs when using their
prescrip0ve authority
(American Nurses Associa0on, 2014)
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Signi%icance
• Using s'mulants to treat ADHD in children has been well
researched and proven to be highly eﬀec've, however, they
hold an abuse poten'al and cause many undesirable side
eﬀects that cause clinicians and parents to prefer not to use
these medica'ons and look to non-s'mulants
(Mar'nez-Raga, Ferreros, Knecht, De Alvaro, & Carabal, 2017)

• American Academy of Pediatrics has a strong
recommenda'on for children and adolescents to be treated
with FDA approved ADHD medica'ons
(American Academy of Family Physicians, 2017)
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Signi%icance
It is highly important to know how to eﬀec5vely treat ADHD in
the pediatric pa5ent due to ADHD’s poten5al nega5ve
outcomes that sustain throughout childhood and extend into
adulthood which are…
• Poorer academic performance which leads to an increased
risk for failing or dropping out
• Rela5onship diﬃcul5es with peers and family members
• Poorer working memory
• More likely to have legal and substance abuse problems
• More prone to injuries
• Increased risk for other comorbid mental health disorders
(Riera, Castells, Tobias, Cunill, Blanco, & Capella, 2017; Roman-Urrestarazu et al., 2016; Kovshoﬀ, Williams, Vrijens,
Danckaerts, Thompson, Yardley, & Sonuga-Barke, 2012; Na5onal Ins5tute of Mental Health, 2017 )
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Theoretical Framework
APPN should understand the pathophysiology of the disease
(ADHD) itself. A prescriber can then choose a medica=on that
has a mechanism of ac=on that targets the pathophysiology of
the disease
• Understanding the role of the dopamine (DA) and
norepinephrine (NE) and their receptors in ADHD is essen:al
to guide the APPN’s prescribing decision-making
• Symptomology of ADHD not only results from a decrease DA
and NE but also can results from an excessive amount,
therefore, there needs to be a moderate level of both DA and
NE for proper prefrontal cortex func:oning thus improving
the symptoms of ADHD
• Overall, there should be a moderate amount of DA to their D1
receptors and moderate amount of NE to their a2A receptors
(Banaschewski et al., 2005; Stahl, 2013)
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De#initions
ADHD: An abbrevia*on for
A-en*on Deﬁcit Hyperac*vity
Disorder, which is a
neurobehavioral disorder
commonly of childhood onset with
three primary symptoms of
ina-en*on, hyperac*vity, and
impulsivity
Pediatric: Generalized term for the
popula*on of children and
adolescents
Children: Human being prior to
puberty; ages 6-12
Adolescents: Human being during
the pubertal *me; ages 13-18.

ER: An abbrevia*on for “extendedrelease” formula*on of a
media*on, which causes a slow,
controlled-release of a medica*on
over a longer period of *me. Similar
names for extended-release are SR
“sustained-release” and CR
“controlled-release”. In some
publica*ons one may see extendedrelease abbreviated as XR
Eﬀec7veness/eﬃcacy: Producing
the desired eﬀect of a medica*on’s
inten*on
Sta7s7cally signiﬁcant: In research,
the rela*onship of a study’s ﬁndings
was not due to chance. The p-value
is less than 5%.
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Process
U"lized the University of North Dakota’s Harley E. French
Library of the Health Sciences
Search Engines and results…
uPubMed: 8 ar"cles were chosen for inclusion into the
literature review
• Limita"ons: last 10 years, peer-reviewed, and English language
• MeSH terms: “ADHD” AND “pediatric” AND “atomoxe"ne”
resulted in 129 ar"cles, “ADHD” AND “pediatric” AND “clonidine
ER” resulted in 24 ar"cles, and “ADHD” AND “pediatric” AND
“guanfacine ER” resulted in 39 ar"cles
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Process
uCINAHL: 4 ar%cles that were chosen to be included in the literature
review

• Limita%ons: 2007-2017, peer-reviewed, English language, and human
subjects
• Boolean Connectors and CINAHL Headings: “ADHD” AND “pediatric”
AND “atomoxe%ne” was searched and resulted in 17 ar%cles,
“ADHD” AND “pediatric” AND “clonidine ER” and resulted in two
ar%cles, and “ADHD” AND “pediatric” AND “guanfacine ER” and
resulted in two ar%cles

uPsycInfo: 3 ar%cles that were chosen to be included in the literature
review
• Limita%ons: 2007-2017, peer-reviewed, English language, and human
subjects
• Boolean Connectors: “ADHD” AND “pediatric” AND “atomoxe%ne”
was searched and resulted in 33 ar%cles, “ADHD” AND “pediatric”
AND “clonidine ER” and resulted in seven ar%cles, and “ADHD” AND
“pediatric” AND “guanfacine ER” and resulted in seven ar%cles

40

EFFECTIVENESS OF NON-STIMULANTS FOR ADHD

Review of Literature
Strong recommenda*on, level A to be prescribed a FDA
approved medica*on for ADHD and/or behavioral therapy
“The evidence is par*cularly strong for s*mulant medica*ons
and suﬃcient but less strong for atomoxe*ne, extended-release
guanfacine, and extended-release clonidine (in that
order)” (American Academy of Pediatrics, 2011, p. 2)
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Literature Review:
Atomoxetine (Strattera)
vDouble blind placebo-control Randomized Control Trial (RCT):
Children/adolescents aged 6-16 years old with ADHD
Took place in Russia
DuraDon of 6-weeks long
Contained 105 paDents with 72 receiving atomoxeDne and 33
receiving the placebo
• Results of this trial were staDsDcally signiﬁcant according to the
ANenDon-Deﬁcit/HyperacDvity Disorder RaDng Scale-IV-Parent
Version (ADHD-RS-IV-Parent) scores
• ComparaDve baseline to treatment response aSer 6 weeks for
atomoxeDne was 72.2% and the placebo 48.5%
• PaDents who received atomoxeDne had a more rapid clinical
outcome response
•
•
•
•

(Martenyi et al., 2010)
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Literature Review:
Atomoxetine (Strattera)
vDouble blind placebo-control RCT
153 children with ADHD ages 8-12 years old
7 week duraBon
ADHDRS-IV-Teacher scale
AtomoxeBne group having 69% decrease of at least 20% in
symptoms of inaNenBon, hyperacBvity, and impulsivity compared
to the placebo of 43.1%
• AtomoxeBne was found to have quick onset of symptom
improvement starBng at only one week
•
•
•
•

(Weiss, et al., 2005)
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Literature Review:
Atomoxetine (Strattera)
vDouble blind RCT comparing Stra6era and Vyvanse
• 200 children with ADHD from ages 6 to 17 years old
• DuraEon of 9 weeks
• Used the Weiss FuncEonal Impairment RaEng Scale-Parent
Report (WFIRS-P)
• AtomoxeEne was found to have staEsEcally signiﬁcant results
showing a decrease in all six domains of the WFIRS-P with the
largest decrease in the family, learning, and school domains

uLimitaEons of these RTCs: short duraEon (atomoxeEne can
take up to 12 weeks or more to reach maximum potenEal),
subjecEve scales, sample size
uStrengths of these RTCs: research designs of randomized
blinded studies, speciﬁc paEent populaEons, and diagnoses
(Nagy, 2016)
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Literature Review:
Atomoxetine (Strattera)
vNon-randomized trial measured the eﬀec4veness of atomoxe4ne
and the s4mulant medica4on methylphenidate
• 30 children with a diagnosis of ADHD ages 6-14
• 12 week dura4on
• Oxyhemoglobin levels measured by near-infrared spectroscopy
(NIRS) was obtained during a Stroop Color-Word Test
• Sta4s4cally signiﬁcant improvements in the stroop color-word test
• Results showed a posi4ve correla4on between age and scores
• NIRS oxyhemoglobin levels had substan4al increases from premedica4on to 12 weeks aQer the start of atomoxe4ne

uLimita4ons: small sample size and their treatment group was not
randomly assigned (assigned by a pediatric psychiatrist)
uStrength: dura4on of study matched dura4on for max eﬀect of
atomoxe4ne
(Nakanishi et al., 2017)
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Literature Review:
Atomoxetine (Strattera)
vMeta-analysis of 25 double-blinded RCTs that compared
atomoxe<ne and a placebo
• Results favored atomoxe<ne over the placebo, 44.6% of pa<ent
had improvement of symptoms of 40% or higher
• There were 39.9% of pa<ent who did not respond with over 25%
improvement of their symptoms
• Results did not diﬀer from children to adolescents

uLimita<ons for the RCTs: generalizing the results to the whole
pediatric ADHD popula<on because only certain pa<ents may
be exposed to the opportunity to par<cipate in these studies
(Schwartz & Correll, 2014)
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Literature Review:
Atomoxetine (Strattera)
vLiterature Review
• Atomoxe0ne was found to be eﬃcacious in children who also
have anxiety or 0c related disorders
• Eﬃcacy was not altered by other comorbid condi0ons
• Health related quality-of-life results were posi0vely correlated
with short and longer term studies
• Children who lack the CYP2D6 enzyma0c pathway or are rapid
metabolizers will have a diﬃcult 0me metabolizing atomoxe0ne
(Kohn, Tsang, & Clarke, 2012)
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Literature Review:
Clonidine ER (Kapvay)
vSystemic Review
• Found clonidine ER eﬀec5ve as monotherapy and as an adjunct
with s5mulant therapy for children with ADHD ages 6-17
(Chan, Fogler, & Hammerness, 2016)

vDouble-blind placebo-control RTC
• 236 children with ADHD ages 6-17 years old
• 8 week dura5on
• Sta5s5cally signiﬁcant results with outcome scales of ADHD-RSIV, Conner’s Parent Ra5ng Scale, Parent Global Assessment, and
Clinical Global Impression of Improvement and Severity Scale
• Clonidine ER saw a quick response to treatment star5ng at soon
as two weeks
uLimita5on: short dura5on and sample size, required same dose
5tra5ons during this 8-week period (limits the individual
therapeu5c needs of the pa5ent)
(Jain, Segal, Kollins, & Khayrallah, 2011)
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Literature Review:
Clonidine ER (Kapvay)
vDouble-blind RCT comparing Clonidine ER, methtylphenidate,
or a combina:on of the two medica:ons
• 122 children with ADHD ages 7-12
• 16 week dura:on
• Conner's Teachers Abbreviated Symptom Ques:onnaire: showed
no improvement in the clonidine ER monotherapy group, but did
show improvement in the combina:on of clonidine ER/
methylphenidate group
• Conner's Abbreviated Symptom Ques:onnaire for Parents and
Children's Global Assessment Scale: showed improvement in
ADHD symptoms whether it was in the Clonidine ER
monotherapy group or the combina:on group
• Clonidine ER was found to be eﬃcacious for certain ADHD pa:ent
subtypes such as those with co-morbid behavioral and/or
impulsive disorders
(Palumbo et al., 2008)
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Literature Review:
Clonidine ER (Kapvay)
vDouble blind RCT that used either clonidine ER or a placebo to
a current s6mulant treatment plan that was not eﬀec6ve
• 198 children and adolescents enrolled over this 8 week study
• Conner Parent Ra6ng Scale, Clinical Global Impression of Severity
and improvement, and Parent Global Assessment, ADHD-RS-IV
scale all found sta6s6cally signiﬁcant improvements in their
scores for the clonidine ER combina6on group
• Star6ng at week 5 the clonidine ER combina6on group started to
show sta6s6cally signiﬁcant results which con6nued throughout
the remainder of the study
uLimita6on: exclusion of comorbid disorders (eliminates many of
the ADHD popula6ons that have co-exis6ng learning or
behavioral disorders), variability in s6mulant medica6ons, no
clonidine ER monotherapy group
uStrength: diverse pa6ent popula6on of males, females, children
and adolescents
(Kollins et al., 2011)
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Literature Review:
Guanfacine ER (Intuniv)
vLiterature Review

• Found guanfacine ER to have profound eﬀects on execu9ve
func9oning in children by improved a>en9on spans, impulse control,
planning, working memory, and distrac9bility
• Improvements in behaviors and motor control were a>ributed to
guanfacine’s eﬀects on the noradrenergic projec9ons to the basal
ganglia and cerebellum
(Strange, 2008)

vDouble blind RCT compares guanfacine ER/s9mulant combina9on
and placebo/s9mulant combina9on

• 461 par9cipants of children/adolescents with ADHD aged 6-17
• 9 week dura9on
• ADHD-RS-IV scale, Clinical Global Impressions of Severity of Illness
and Improvement scales
• Signiﬁcant improvement in scores for all assessment scales for the
guanfacine ER/s9mulant group verses the placebo/s9mulant group
uLimita9on: short dura9on, requirement was for a par9al response in
s9mulant therapy already before entering the trial
(Wilens et al., 2012)
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Literature Review:
Guanfacine ER (Intuniv)
vDouble blind RCT with placebo-control
329 children/adolescents aged 6 to 17 years old with ADHD
9 week duraCon
Guanfacine ER was divided into 3 separate dosage groups
Improvements in ADHD-RS-IV was reported for all three
guanfacine ER dosage groups showing a reducCon in score of
19.6, compared to the placebo which had a reducCon of 12.2
uLimitaCons: short 9 week trial duraCon and a small number of
adolescents compared to children
uStrength: Strict inclusion and exclusion criteria
•
•
•
•

(Sallee et al., 2009)
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Literature Review:
Guanfacine ER (Intuniv)
vDouble blind RCT with placebo-control
345 children/adolescents aged 6-17 years old with ADHD
8 week duraDon
3 diﬀerent guanfacine ER dosage groups
Average change in ADHD-RS-IV scores for the guanfacine ER
groups were 17.16 and the placebo group was 8.48
• Secondary eﬃcacy scales of Clinical Global Impression of
Improvement, Parent's Global Assessment, Conners’ Parent and
Teacher RaDng Scale–Revised, and Conners’ Teacher RaDng
Scale–revised found signiﬁcant improvements in the guanfacine
ER groups
uLimitaDons: short duraDon
•
•
•
•

(Biederman et al., 2008)
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Literature Review:
Guanfacine ER (Intuniv)
vLiterature review
• Guanfacine ER was found to be favorable for pediatric pa7ents
with ADHD that had dominant opposi7onal symptoms
• Found varying results in the eﬃcacy onset of guanfacine ER,
ranging from 1-4 weeks
• Combina7on therapy with a s7mulant was found to be beneﬁcial
in children who were not experiencing the full treatment
poten7al of s7mulant medica7ons
• ADHD-RS-IV scores saw improvements with guanfacine ER/
s7mulant combina7on therapy in children with opposi7on
symptoms and those without
(Faraone, McBurneP, Sallee, Steeber, & López, 2013; Childress & Berry, 2012)
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Results
• Fi#een ar)cles included nine RCTs, three literature reviews,
one non-randomized study, one meta-analysis, and one
systemic review
• RCT studies were found to be very beneﬁcial because there
was elabora)on on the speciﬁc types of outcome
measurement tools that were u)lized
• Most common scale that was used was the ADHD-RS-IVParent and the Clinical Global Impression and Severity Scale
• Most of these scales had either a parent/guardian or teacher
comple)ng the scale
• The non-randomized study did not use a scale; the Stroop
Word-Color Test and NIRS score was performed instead
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Results
vSix ar'cles studied the eﬀec'veness of atomoxe'ne:
§ All 6 ar'cles agreed atomoxe'ne was an eﬀec've medica'on for
the treatment of ADHD in the pediatric popula'on with
sta's'cally signiﬁcant results
§ Two ar'cles found atomoxe'ne to have more rapid onset than
the placebo
§ One study found the NIRS exam to have increased prefrontal
cortex ac'vity especially in the leF lateral frontal lobe when on
atomoxe'ne
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Results
vFour ar'cles studied the eﬀec'veness of clonidine ER:
• All 4 ar'cles agreed clonidine ER was an eﬀec've medica'on for
the treatment of ADHD in the pediatric popula'on with
sta's'cally signiﬁcant results
• Two out of the three RCT’s compared the eﬀec'veness of
clonidine ER as an adjunct medica'on to s'mulant treatment
• One systemic review highly supported its use as an adjunct
medica'on to s'mulant therapy and found clonidine ER to be
more helpful with behavioral symptoms
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Results
vFive ar(cles studied the eﬀec(veness of guanfacine ER:
• All 5 ar(cles agreed guanfacine ER was an eﬀec(ve medica(on
for the treatment of ADHD in the pediatric popula(on with
sta(s(cally signiﬁcant results
• Three ar(cles found guanfacine ER to be an eﬀec(ve adjunct to
s(mulant treatment
• One ar(cle found guanfacine ER to be speciﬁcally eﬃcacious in
children with opposi(onal symptoms
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Implications in…
Nursing Prac,ce

Research

• Choosing to prescribe nons0mulants over the best
prac0ce guideline of s0mulants,
can demonstrate how the APPN
is providing holis0c care by
addressed all aspects of the
pa0ents needs and concerns
• Con0nue to further one’s
educate is very important
because new evidence-based
research becomes published
and knowledge behind
understanding the brain and
how it relates to ADHD is
increasing

• Limited research on nons0mulant monotherapy; many
ar0cles were evalua0ng
s0mulant therapy and/or
s0mulant with adjunct nons0mulant therapy
• More research is needed to
determine what outcome
measurement scale is best to
determine eﬀec0veness of a
medica0on, studies with longer
dura0on, greater sample size,
and with a focused
monotherapy experimental
group to strength the validity of
their ﬁndings
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Implications in…
Educa&on

Health Policy

• It is important for the
APPN to be educated on
medica6ons, including
their evidence-based
research, to guide
treatment decisions and to
provide pyschoeduca6on
to their pa6ents

• Policies at hospitals,
outpa6ent seJngs, and
state levels can be
impacted by the results of
this literature review by
APPN’s advoca6ng for
updated policies for
treatment op6ons
• APPN can support
con6nuing research by
having their pa6ent enroll
in research studies

(American Nurses Associa6on, 2014)

• With knowledge of the
evidence-based research,
the APPN can educate the
pa6ent and their parents/
guardians regarding its
eﬀec6veness and how the
medica6on will target the
core symptoms of ADHD

60

EFFECTIVENESS OF NON-STIMULANTS FOR ADHD

Conclusion
• ADHD is a complex disorder with the poten5al to leave
profound eﬀects on one’s childhood and development when
not treated eﬀec5vely
• Atomoxe5ne, clonidine ER, and guanfacine ER were found to
have sta5s5cally signiﬁcant results despite the use of diﬀering
yet similar outcome measurement scales
• Con5nuing research is needed to maintain these medica5ons
as treatment op5ons for this popula5on
With the results of this literature review, the APPN can make
evidence-based decisions during treatment planning for their
pediatric pa=ent with ADHD
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